14-day hybrid therapy and 10-day bismuth quadruple therapy ideal first-line treatment for H.Pylori infection
Taiwan: According to a study published in AJG, American Journal of Gastroenterology, researchers have found 14-day hybrid therapy and 10-day bismuth quadruple therapy to be more effective in treating H. pylori infection than the 14-day high-dose dual therapy as the first-line treatment.
Researchers comparatively evaluated how safe and efficacious 14-day hybrid therapy, 14-day high-dose dual therapy, and 10-day bismuth quadruple therapy are for managing H. pylori infections in the first-line treatment.
They recruited patients with relevant histories from nine centres in Taiwan and randomly assigned them in a ratio of 1:1:1 to the three aforementioned therapies. The rate of eradication of H pylori assessed in the intention-to-treat population was the primary outcome measured in the study.
The study results could be summarised as follows:
- Nine hundred eighteen patients were assigned randomly (August 2018-December 2021).
- The intention-to-treat eradication rates for 14-day hybrid therapy, 14-day high-dose dual therapy and 10-day bismuth quadruple therapy were 91.5%, 83.3% and 90.2%, respectively.
- Both hybrid therapy (difference: 8.2%) and bismuth quadruple therapy (difference: 6.9%) were superior to high-dose dual treatment, and there were similarities to one another.
- The adverse events frequency for 14-day hybrid therapy, 14-day high dose dual therapy, and 10-day bismuth quadruple therapy was 27%, 13% (40/305) and 32%, respectively.
- There were few adverse events in patients receiving high-dose dual therapy.
Concluding further, as per the study studies findings, there was more effectiveness reported with 14-day hybrid therapy, and 10-day bismuth quadruple therapy is more effective compared to 14-day high-dose dual therapy in the first-line treatment of H. pylori infection in Taiwan.
The researchers also reported that there are few side effects with high-dose dual therapy compared to the hybrid bismuth quadruple treatments.
Further reading:
Hsu, Ping-I et al. Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial. The American Journal of Gastroenterology ():10.14309/ajg.0000000000002255, March 20, 2023. | DOI: 10.14309/ajg.0000000000002255
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.